References
- World Health Organization. Global Tuberculosis Report; 2018 [cited 2019 Oct 25]. https://www.who.int/tb/publications/global_report/en/
- Mirsaeidi M, Sadikot RT. Patients at high risk of tuberculosis recurrence. Int J Mycobacteriol. 2018;7(1):1–6.
- Panjabi R, Comstock G, Golub J. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis. 2007;11(8):828–837.
- Jindani A, Nunn A, Enarson D. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364(9441):1244–1251.
- Anaam M, Ibrahim MI, Al Serouri A, et al. A nested case-control study on relapse predictors among tuberculosis patients treated in Yemen's NTCP. Public health action. 2012;2(4):168–173.
- Prasad R, Verma S, Shrivastava P, et al. A follow up study on revised national tuberculosis control programme (RNTCP): results from a single centre study. Lung India. 2008;25(4):142–144.
- Johnson J, Okwera A, Nsubuga P. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Int J Tuberc Lung Dis. 2000;4(11):1032–1040.
- Vree M, Huong N, Duong B, et al. Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam. Int J Tuberc Lung Dis. 2007;11(4):392–397.
- Lee H, Kim J. A study on the relapse rate of tuberculosis and related factors in Korea using nationwide tuberculosis notification data. Osong Public Health Res Perspect. 2014;5:S8–S17.
- Tailor MK. Relapse at 5 years in Indian revised national tuberculosis control programme cat I DOTS regimen. Chest. 2005;128(4):404S.
- Rosser A, Marx F, Pareek M. Recurrent tuberculosis in the pre-elimination era. Int J Tuberc Lung Dis. 2018;22(2):139–150.
- Othman GQ, Ibrahim NIM, Raja’a YA. Costs associated with tuberculosis diagnosis and treatment in Yemen for patients and public health services. East Mediterr Health J. 2012;18(4):393–398.
- Anaam MS, Ibrahim MIM, Al Serouri AW, et al. Cost of tuberculosis relapse in Yemen: a nested case-control study. JPPCM. 2017;3(2):58–65.
- Anderson de Cuevas R, Al-Sonboli N, Al-Aghbari N, et al. Barriers to completing TB diagnosis in Yemen: services should respond to patients' needs. PLoS One. 2014;9(9):e105194.
- Aldhubhani, A, Izham, M M, Pazilah, I, et al. Effect of delay in diagnosis on the rate of tuberculosis among close contacts of tuberculosis patients. East Mediterr Health J. 2013;19(10):837–842. doi:10.26719/2013.19.10.837.
- World Health Organization. TB in Yemen: country profile; 2018 [cited 2019 Oct 25]. https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=YE&LAN=EN&outtype=pdf
- Othman, Q. Ibrahim MI, Raja’a YA. Health related quality of life of pulmonary and extrapulmonary tuberculosis patients in Yemen. Afr J Pharm Pharmacol. 2011;5(4):547–553. doi:10.5897/AJPP11.078.
- National Tuberculosis Control Programme. Tuberculosis control programme manual. 2nd ed. Sana’a: Ministry of Health and Population of Yemen, NTCP; 2015.
- World Health Organization. Management of tuberculosis: training for health facility staff. Geneva: World Health Organization; 2003.
- Zong Z, Huo F, Shi J. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Front microbiol. 2018;9:1858.
- Lambert M-L, Hasker E, Van Deun A, et al. Lancet Infect Dis. 2003;3(5):282–287.
- Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358(9294):1687–1693.
- Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005;171(12):1430–1435.
- Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol. 2001;39(6):2213–2218.
- Cacho J, Meixeira AP, Cano I, et al. Recurrent tuberculosis from 1992 to 2004 in a metropolitan area. Eur Respir J. 2007;30(2):333–337.
- Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med. 2004;170(12):1360–1366.
- Shen G, Xue Z, Shen X, et al. Recurrent tuberculosis and exogenous reinfection, Shanghai, China. Emerg Infect Dis. 2006;12(11):1776.
- van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999;199 9341(16):1174–1179.
- Bacakoğlu F, Başoğlu ÖK, Çok G, et al. Pulmonary tuberculosis in patients with diabetes mellitus. Respiration. 2001;68(6):595–600.
- Driver CR, Munsiff SS, Li J, et al. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin infect dis. 2001;33(10):1762–1769.
- Andreu J, Caceres J, Pallisa E, et al. Radiological manifestations of pulmonary tuberculosis. European journal of radiology. 2004;51(2):139–149.
- Lang T. Documenting research in scientific articles: guidelines for authors: 3. Reporting multivariate analyses. Chest. 2007;131(2):628–632.
- Gadoev J, Asadov D, Harries AD, et al. Recurrent tuberculosis and associated factors: a five - year countrywide study in Uzbekistan. PLoS One. 2017;12(5):e0176473.
- Millet J-P, Shaw E, Orcau À, et al. Tuberculosis recurrence after completion treatment in a European city: reinfection or relapse? PloS one. 2013;8(6):e64898.
- Hung CL, Chien JY, Ou CY. Associated factors for tuberculosis recurrence in Taiwan: a nationwide nested case-control study from 1998 to 2010. PLoS One. 2015;10(5):e0124822.
- El Sahly H, Wright J, Soini H, et al. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis. 2004. 8(3):333–340.
- Anaam MS, Mohamed Ibrahim MI, Al Serouri AW, et al. Factors affecting patients' compliance to anti‐tuberculosis treatment in Y emen. J Pharm Heal Serv Res. 2013;4(2):115–122.
- Ali MH, Alrasheedy AA, Hassali MA, et al. Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan. Antibiotics. 2019;8(3):90.
- d’Arc L, Batista J, de Fátima Pessoa Militão de Albuquerque M, de Alencar Ximenes RA, et al. Smoking increases the risk of relapse after successful tuberculosis treatment. Int J Epidemiol. 2008;37(4):841–851.
- Jee SH, Golub JE, Jo J, et al. Smoking and risk of tuberculosis incidence, mortality, and recurrence in South Korean men and women. Am J epidemiol. 2009;170(12):1478–1485.
- Thomas A, Gopi P, Santha T, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis. 2005;9(5):556–561.
- Davies P, Yew W, Ganguly D, et al. Smoking and tuberculosis: the epidemiological association and immunopathogenesis. Trans R Soc Trop Med Hyg. 2006;100(4):291–298.
- Boelaert JR, Gomes MS, Gordeuk VR. Smoking, iron, and tuberculosis. Lancet. 2003;362(9391):1243–1244.
- Chang KC, Leung CC, Yew WW, et al. A nested case–control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004;170(10):1124–1130.
- Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528–534.
- Huang Q, Yin Y, Kuai S, et al. The value of initial cavitation to predict re-treatment with pulmonary tuberculosis. Eur J Med Res. 2016;21(1):20.
- Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J. 2011;37(2):441–462.
- World Health Organization. Treatment of tuberculosis: guidelines 4th ed.; 2010 [cited 2019 Oct 25]. https://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf;jsessionid=B654FC3FAB3DE86462595675B90D20C4?sequence=1
- World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update [cited 2019 Oct 25]. https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf?sequence=1
- Bashar M, Alcabes P, Rom WN, et al. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001;120(5):1514–1519.
- Lee PH, Lin HC, Huang AS, et al. Diabetes and risk of tuberculosis relapse: nationwide nested case-control study. PLoS One. 2014;9(3):e92623.
- Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013;68(3):214–220.
- World Health Organization. Tuberculosis and diabetes; 2016 [cited 2019 Oct 25]. https://www.who.int/tb/publications/diabetes_tb.pdf?ua=1
- Picon PD, Bassanesi SL, Caramori MLA, et al. Risk factors for recurrence of tuberculosis. J Bras Pneumol. 2007;33(5):572–578.
- World Health Organization. A patient-centred approach to TB care. 2018; [cited 2019 Oct 25]. https://apps.who.int/iris/bitstream/handle/10665/272467/WHO-CDS-TB-2018.13-eng.pdf?ua=1
- World Health Organization. Nutritional care and support for patients with tuberculosis; 2013 [cited 2019 Oct 25]. https://www.who.int/tb/TBnutrition.pdf?ua=1
- The World Bank. Nutrition at a glance in Yemen. [cited 2019 Oct 25]. http://siteresources.worldbank.org/NUTRITION/Resources/281846-1271963823772/Yemen.pdf
- Khan A, Sterling TR, Reves R, et al. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med. 2006;174(3):344–348.